Damaraju, ChandrasekharRao Venkata
Janssen Research & Development (United States)
4 papers on CoChatORCID 0000-0003-4925-4987
Most cited papers
- Verified
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet
Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases
Cited by 752
- Verified
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 245
- Verified
The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 167
- Verified
Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension
Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension
Blood Pressure and Hypertension StudiesDiabetes Treatment and Management
Cited by 85
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free